ClinicalTrials.gg
Not yet recruitingNCT02726256Updated Apr 18, 2016

G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)

An observational study in Type 2 Diabetes and Impaired Glucose Intolerance, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-04-18.

Sponsored by Yonsei University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetes Mellitus, Type 2 by Yonsei University — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Yonsei University.

Started
2007
the only one that year
Observational
7 of 20
2 open now
Registered
8th of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, this one is the only one that started in 2007, is one of 7 observational ones, and was the 8th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, or all of them as a file.
02

Study summary

The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. Diabetes develops due to glucose intolerance. Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. This study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.

03

Conditions studied

  • Type 2 Diabetes
  • Impaired Glucose Intolerance

Keywords

  • Diabetes
  • DM complication
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with either type 2 diabetes or impaired glucose toloerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients older than 20 years old who has visited Gangnam severance hospital since January 2007.
  2. Patients with either diabetes or impaired glucose tolerance
  3. Patients with at least 6 months of follow-up period

Exclusion criteria

Exclusion Criteria:

  1. Patients with gestational diabetes, any active stage of cancer and severe disability
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Diabetes and Impaired glucose Tolerance (G-CREDIT)

    Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.

06

What researchers measure

Primary outcomes

  1. Life style assessment - Past medical history - Smoking, alcohol history - Sleep, exercise, daily activity check - Diet - Reproductive status (Women only) - Socioeconomic status

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  2. Past medical history

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  3. Smoking, alcohol history

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  4. Sleep, exercise, daily activity check

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  5. Diet

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  6. Reproductive status (Women only)

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  7. Socioeconomic status

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  8. Anthropometric measurements : Height, weight, waist circumference, pulse rate, blood pressure

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  9. SMA, TG, HDL, LDLM apoA, apoB

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  10. PC2hrs, HbA1C, Insulin, C-peptide (AC, PC2hr), hs-CRP

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  11. Urine protein, albumin, creatinine

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  12. EKG, Neurometer, Chest PA, Abdominal sonography

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  13. Fundus photography, fat computed tomography

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

  14. HOMA-IR, HOMA-β

    Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications

    Time frame: an expected average of 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — This study has a plan to share data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2026 and a completion of Feb 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2016
First posted
Apr 1, 2016
Start
Jan 2007
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Apr 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02726256
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Jan 2007
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Apr 18, 2016

Study contacts

Chul Woo Ahn, MD
Contact
acw@yuhs.ac
82-02-2019-3339

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion